Open discussion

Clinical Cancer Research

Volumn 13, Issue 2 II, 2007, Pages

  Atkins, ^a   Wood, ^a   Kwon, ^a   Figlin, ^a   Libermann, ^a   Rini, ^a   Flaherty, ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; BEVACIZUMAB; SORAFENIB; SUNITINIB; ALPHA INTERFERON; CANCER VACCINE; INTERLEUKIN 2; MEDROXYPROGESTERONE ACETATE; THALIDOMIDE; VINBLASTINE;

CANCER GRADING; CANCER GROWTH; CANCER SIZE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; KIDNEY CARCINOMA; NOTE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TOXICITY; TREATMENT RESPONSE; ADJUVANT THERAPY; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; GENE TARGETING; HISTOPATHOLOGY; HORMONAL THERAPY; MULTIMODALITY CANCER THERAPY; NEPHRECTOMY; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; KIDNEY NEOPLASMS; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; NEPHRECTOMY; PROGNOSIS; TREATMENT OUTCOME;

EID: 33846867459     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2109     Document Type: Note

References (42)

1. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001;166:1611-23.
2. Levy DA, Slaton JW, Swanson DA, Dinney CP. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 1998;159:1163-7.
3. Frank I, Blute ML, Leibovich BC, Cheville JC, Lohse CM, Zincke H. Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol 2005;173:1889-92.
4. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001;19:1649-57.
5. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade, and necrosis: the SSIGN score. J Urol 2002;168:2395-400.
6. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001;166:63-7.
7. Cindolo L, de la Taille A, Messina G, et al. A preoperative clinical prognostic model for non-metastatic renal cell carcinoma. BJU Int 2003;92:901-5.
8. Yaycioglu O, Roberts WW, Chan T, Epstein JI, Marshall FF, Kavoussi LR. Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model. Urology 2001;58:141-5.
9. Lam JS, Leppert JT, Figlin RA, Belldegrun AS. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology 2005;66:1-9.
10. Rabinovitch R, Zelefsky M, Gaynor J, Fuks Z. Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J Clin Oncol 1994;12:206-12.
11. Juusela H, Malmio K, Alfthan O, Oravisto KJ. Preoperative irradiation in the treatment of renal adenocarcinoma. Scand J Urol Nephrol 1977;11:277-81.
12. Finney R. The value of radiotherapy in the treatment of hypemephroma - a clinical trial. Br J Urol 1973;45:258-69.
13. Pizzocaro G, Piva L, Di Fronzo G, et al. Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study. J Urol 1987;138:1379-81.
14. Vogelzang NJ, Priest ER, Borden L. Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup. J Urol 1992;148:1247-8.
15. Finke JH, Tubbs R, Connelly B, Pontes E, Montie J. Tumor-infiltrating lymphocytes in patients with renal-cell carcinoma. Ann NY Acad Sci 1988;532:387-94.
16. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133-41.
17. Lam JS, Leppert JT, Belldegrun AS, Figlin RA. Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol 2005;23:202-12. Epub 2005 Apr 5.
18. Arya M, Chao D, Patel HR. Allogeneic hematopoietic stem-cell transplantation: the next generation of therapy for metastatic renal cell cancer. Nat Clin Pract Oncol 2004;1:32-8.
19. Clark JI, Atkins MB, Urba WJ, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 2003;21:3133-40.
20. Atzpodien J, Schmitt E, Gertenbach U, et al. Adjuvant treatment with interleukin-2- and interferon-α2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 2005;92:843-6.
21. Prummer O. Interferon-α antibodies in patients with renal cell carcinoma treated with recombinant interferon-α-2A in an adjuvant multicenter trial. The Delta-P Study Group. Cancer 1993;71:1828-34.
22. Pizzocaro G, Piva L, Colavita M, et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 2001;19:425-31.
23. Messing EM, Manola J, Wilding G, et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup Trial. J Clin Oncol 2003;21:1214-22.
24. Basting R, Corvin S, Handel D, Hinke A, Schmidt D. Adjuvant immunotherapy in renal cell carcinoma - comparison of interferon α treatment with an untreated control. Anticancer Res 1999;19:1545-8.
25. Jeon SH, Chang SG, Kim JI. The role of adjuvant immunotherapy after radical nephrectomy and prognostic factors in pT3N0M0 renal cell carcinoma. Anticancer Res 1999;19:5593-7.
26. Migliari R, Muscas G, Solinas A, et al. Is there a role for adjuvant immunochemotherapy after radical nephrectomy in pT2-3N0M0 renal cell carcinoma? J Chemother 1995;7:240-5.
27. Hong SK, Kwak C, Lee SE. Adjuvant interleukin-2, interferon-α, and 5-fluorouracil immunochemotherapy after radical nephrectomy for locally advanced renal cell carcinoma. Urology 2005;66:518-22.
28. Zielinski H, Szmigielski S, Petrovich Z. Comparison of preoperative embolization followed by radical nephrectomy with radical nephrectomy alone for renal cell carcinoma. Am J Clin Oncol 2000;23:6-12.
29. Sanchez-Ortiz RF, Tannir N, Ahrar K, Wood CG. Spontaneous regression of pulmonary metastases from renal cell carcinoma after radio frequency ablation of primary tumor: an in situ tumor vaccine? J Urol 2003;170:178-9.
30. Galligioni E, Quaia M, Merlo A, et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmene-Guerin: five-year results of a prospective randomized study. Cancer 1996;77:2560-6.
31. Jocham PD, Richter A, Hoffmann L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004;363:594-9.
32. Kader AK, Wood CG. Adjuvant therapy for renal cell carcinoma: targeted approaches. In: Renal cell carcinoma: molecular targets and clinical applications. Bukowski, Motzer, Figlin, editors. The Humana Press, in press.
33. Antigenics, Inc. Press release. NewYork, NY, 2006.
34. Daliani DD, Papandreou CN, Thall PF, et al. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer 2002;95:758-65.
35. Haas N. Update on targeted therapy adjuvant trials (ECOG/MRC). As presented at the Fifth International Symposium of the Kidney Cancer Association, 2006, Chicago, Illinois.
36. Kawata N, Yagasaki H, Yuge H, et al. Histopathologic analysis of angiogenic factors in localized renal cell carcinoma: the influence of neoadjuvant treatment. Int J Urol 2001;8:275-81.
37. Flanigan RC. Debulking nephrectomy in metastatic renal cancer. Clin Cancer Res 2004;10:6335-41S.
38. Wood CG. The role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma. Urol Clin North Am 2003;30:581-8.
39. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345:1655-9.
40. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R; European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358:966-70.
41. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171:1071-6.
42. Pantuck AJ, Belldegrun AS, Figlin RA. Nephrectomy and interleukin-2 for metastatic renal cell carcinoma. N Engl J Med 2001;345:1711-2.